Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22012084 | 0.95 | KMT2A (0.44) | NR1H2NR1H3MEN1KMT2ARIPK1 | |
| SCHEMBL22012883 | 0.89 | STS (0.43) | NR1H2NR1H3MEN1KMT2ASTS | |
| SCHEMBL25033880 | 0.84 | KMT2A (0.46) | NR1H2NR1H3MEN1KMT2ASTS | |
| SCHEMBL21962575 | 0.79 | GPR119 (0.50) | NR1H2NR1H3MEN1KMT2ASTS | |
| SCHEMBL20680936 | 0.78 | CHRNB2 (0.43) | — | |
| SCHEMBL22012882 | 0.77 | NR1H2 (0.40) | NR1H2NR1H3MEN1KMT2ASTS | |
| SCHEMBL22012885 | 0.77 | NR1H2 (0.40) | NR1H2NR1H3MEN1KMT2ASTS | |
| SCHEMBL25031647 | 0.76 | NLRP3 (0.38) | NR1H2NR1H3MEN1KMT2ANPC1 | |
| SCHEMBL14880733 | 0.73 | NR1H2 (0.54) | NR1H2NR1H3KMT2ARIPK1 | |
| SCHEMBL29514552 | 0.73 | RIPK1 (0.48) | NR1H2NR1H3GPR119RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NR1H2 334/4885NR1H3 409/4885MEN1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.